US 4436727A
· Ribi
· 1984
[cited by applicant]
US 4866034A
· Ribi
· 1989
[cited by applicant]
US 4877611A
· Cantrell
· 1989
[cited by applicant]
US 4912094A
· Myers et al.
· 1990
[cited by applicant]
US 5057540A
· Kensil et al.
· 1991
[cited by applicant]
US 6005099A
· Davies et al.
· 1999
[cited by applicant]
US 6303347B1
· Johnson et al.
· 2001
[cited by applicant]
US 6764840B2
· Johnson et al.
· 2004
[cited by applicant]
US 8258268B2
· Wu et al.
· 2012
[cited by applicant]
US 9181349B2
· Baurin et al.
· 2015
[cited by applicant]
US 9676857B2
· Dimitrov et al.
· 2017
[cited by applicant]
US 20030119733A1
· Cerami et al.
· 2003
[cited by applicant]
US 20090075404A1
· Matsunami
· 2009
[cited by applicant]
US 20170035871A1
· Ueno et al.
· 2017
[cited by applicant]
CN 101190946A
· 2008
[cited by applicant]
EP 0109942B1
· 1991
[cited by applicant]
EP 0362279B1
· 1995
[cited by applicant]
EP 0729473B1
· 2000
[cited by applicant]
WO 9421292A1
· 1994
[cited by applicant]
WO 9509917A1
· 1995
[cited by applicant]
WO 9514026A1
· 1995
[cited by applicant]
WO 9611711A1
· 1996
[cited by applicant]
WO 9633739A1
· 1996
[cited by applicant]
WO 9850399A1
· 1998
[cited by applicant]
WO 9964301A1
· 1999
[cited by applicant]
WO 0000462A1
· 2000
[cited by applicant]
WO 0146127A1
· 2001
[cited by applicant]
WO 03011223A2
· 2003
[cited by applicant]
WO 03043572A2
· 2003
[cited by applicant]
WO 03099195A2
· 2003
[cited by applicant]
WO 2008143954A2
· 2008
[cited by applicant]
WO 2009075404A1
· 2009
[cited by applicant]
WO 2009099961A2
· 2009
[cited by applicant]
WO 2010112193A1
· 2010
[cited by applicant]
WO 2010115589A1
· 2010
[cited by applicant]
WO 2012051097A1
· 2012
[cited by applicant]
WO 2012131555A2
· 2012
[cited by applicant]
WO 2014028644A1
· 2014
[cited by applicant]
WO 2016087416A1
· 2016
[cited by applicant]
WO WO2017163049A1
· 2017
[cited by examiner]
WO 2017193032A2
· 2017
[cited by applicant]
Skolnick et al. (Trends in Biotechnology 18: 34-39, 2000).
[cited by examiner]
Greenspan et al. (Nature Biotechnology 7: 936-937, 1999).
[cited by examiner]
Giusti et al. (Proc. Natl. Acad. Sci. USA. May 1987; 84 (9): 2926-2930).
[cited by examiner]
Winkler et al (J. Imm., 265:4505-4514, 2000).
[cited by examiner]
Sela-Culang et al. (Frontiers in Immunology, 2013 vol. 4, article 302, pp. 1-13).
[cited by examiner]
Tan et al. (Nature Medicine vol. 24 No. 4, pp. 401-407). (Year: 2018).
[cited by examiner]
Foquet et al. (Journal of Clinical Investigation, vol. 124 No. 1, pp. 140-144). Jan. 2014.
[cited by examiner]
Chien et al. (Proc. Natl. Acad. Sci. USA. Jul. 1989; 86 (14): 5532-5536).
[cited by examiner]
Caldas et al. (Mol. Immunol. May 2003; 39 (15): 941-952).
[cited by examiner]
Casadevall et al. (PNAS vol. 109 No. 31, pp. 12272-12273). Jul. 31, 2012.
[cited by examiner]
Charoenvit et al., “Development of Two Monoclonal Antibodies against
[cited by applicant]
Clement et al., “Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite
[cited by applicant]
Foquet et al., “Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent
[cited by applicant]
International Search Report and Written Opinion, dated Dec. 3, 2018, for International Application No. PCT/EP2018/060113, 21 pages.
[cited by applicant]
López et al., “Immunogenicity of Synthetic Peptides Corresponding to the Nonrepeat Regions of the
[cited by applicant]
Peng et al., “Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection,”
[cited by applicant]
Swearingen et al., “Interrogating the
[cited by applicant]
Wilson et al., “ Recognition of phage-expressed peptides containing Asx-Pro sequences by monoclonal antibodies produced against
[cited by applicant]
Young et al., “Expression of
[cited by applicant]
“Extract from the Clinical Evaluation Report for blinatumomab,” AusPAR Attachment 2, Australian Government, Department of Health, Therapeutic Good Administration, 2018.
[cited by applicant]
Ahmad et al., “scFv Antibody: Principles and Clinical Application,”
[cited by applicant]
Beiboer et al., “Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics yet Structural Divergence Between the Original Murine Antibody and its Human Equivalent,”
[cited by applicant]
Brinkmann et al., “The making of bispecific antibodies,”
[cited by applicant]
Du et al. “Engineering Bifunctional Antibodies with Constant Region Fusion Architectures”
[cited by applicant]
Giudicelli et al., “IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin ant T cell receptor genes”
[cited by applicant]
Golay et al. “Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies”,
[cited by applicant]
Janeway's Immunobiology (Murphy, Kenneth and Weaver, Casey, Janeway's Immunobiology, 9th Ed. 2017, Garland Science, pp. 140-148 and 415.
[cited by applicant]
Klimka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,”
[cited by applicant]
Muda et al., “Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies”,
[cited by applicant]
Product Package Insert, ABECMA® (idecabtagene vicleucel), suspension for intravenous infusion, 2021.
[cited by applicant]
Product Package Insert, BLINCYTO® (blinatumomab) for injection for intravenous use, 2021.
[cited by applicant]
Product Package Insert, BREYANZI® (lisocabtagene maraleucel) suspension for intravenous infusion, 2021.
[cited by applicant]
Product Package Insert, KYMRIAH® (tisagenlecleucel) suspension for intravenous infusion, 2021.
[cited by applicant]
Product Package Insert, TECARTUS™ (brexucabtagene autoleucel) suspension for intravenous infusion, 2021.
[cited by applicant]
Product Package Insert, YESCARTA® (axicabtagene ciloleucel) suspension for intravenous infusion, 2021.
[cited by applicant]
Rader et al. “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,”
[cited by applicant]
Tudor et al. “Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody,”
[cited by applicant]
Wozniak-Knopp et al., “An antibody with Fab-constant domains exchanged for a pair of CH3 domains”,
[cited by applicant]
Wu et al., “Blinatumomab: a bispecific T cell engage (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia,”
[cited by applicant]
ASTMH 63rd Annual Meeting, Nov. 2-6, 2014, pp. 491, 1607.
[cited by applicant]
Armour et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities,”
[cited by applicant]
Baker et al., “Structures of bovine and human papillomaviruses: Analysis by cryoelectron microscopy and three-dimensional image reconstruction,”
[cited by applicant]
Birkholz et al., “Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation,”
[cited by applicant]
Burton, “Immunoglobulin G: Functional sites,”
[cited by applicant]
Capel et al., “Heterogeneity of human IgG Fc receptors,”
[cited by applicant]
Casal, “Use of parvovirus-like particles for vaccination and induction of multiple immune responses,”
[cited by applicant]
Chu et al., “Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγIIb with Fc-engineered antibodies,”
[cited by applicant]
Coppi et al., “The
[cited by applicant]
Crompton et al., “Malaria Immunity in Man and Mosquito: Insights into Unsolved Mysteries of a Deadly Infectious Disease,”
[cited by applicant]
De Haas et al., “Fcγ receptors of phagocytes,”
[cited by applicant]
Duncan et al., “The binding site for Clq and IgG,”
[cited by applicant]
Flower, “Designing immunogenic peptides,”
[cited by applicant]
Ganesan et al., “FcγRIIb on liver sinusoidal endothelium clears small immune complexes,”
[cited by applicant]
Gessner et al., “The IgG Fc receptor family,”
[cited by applicant]
Goldmann et al., “Molecular Cloning and Expression of Major Structural Protein VP1 of the Human Polyomavirus JC Virus: Formation of Virus-Like Particles Useful for Immunological and Therapeutic Studies,”
[cited by applicant]
Hagensee et al., “Three-Dimensional Structure of Vaccinia Virus-Produced Human Papillomavirus Type 1 Capsids,”
[cited by applicant]
Hurtado et al., “Identification of Domains in Canine Parvovirus VP2 Essential for the Assembly of Virus-Like Particles,”
[cited by applicant]
Hutten et al., “CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses,”
[cited by applicant]
Huysamen et al., “CLEC9A Is a Novel Activation C-type Lectin-like Receptor Expressed on BDCA3
[cited by applicant]
Izard et al., “Principles of quasi-equivalence and Euclidean geometry govern the assembly of cubic and dodecahedral cores of pyruvate dehydrogenase complexes,”
[cited by applicant]
Jaoudé et al., “Role of the Antigenic Loop of the Hepatitis B Virus Envelope Proteins in Infectivity of Hepatitis Delta Virus,”
[cited by applicant]
Jiang et al., “Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles,”
[cited by applicant]
Kanekiyo et al., “Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies,”
[cited by applicant]
Kang et al., “Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles,”
[cited by applicant]
Li et al., “Expression and Self-Assembly of Empty Virus-Like Particles of Hepatitis E Virus,”
[cited by applicant]
Lohcharoenkal et al., “Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy,”
[cited by applicant]
Menard, “The journey of the malaria sporozite through its hosts: two parasite proteins lead the way,”
[cited by applicant]
Notka et al., “Construction and Characterization of Recombinant VLPs and Semliki-Forest Virus live Vectors for Comparative Evaluation in the SHIV Monkey Model,”
[cited by applicant]
Ravetch et al., “Fc Receptors,”
[cited by applicant]
Salisse et al., “A Functional Essential to Viral Entry Underlies the Hepatitis B Virus “a” Determinant,”
[cited by applicant]
Schneider-Ohrum et al., “Virus-like particles for antigen delivery at mucosal surfaces,”
[cited by applicant]
Schreibelt et al., “The C-type lectin receptor CLEC9A mediates antigen uptake and cross- presentation by human blood BDCA3+ myeloid dendritic cells,”
[cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgGI for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgGI Variants with Improved Binding to the FcγR,”
[cited by applicant]
Sinnis et al., “Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein,”
[cited by applicant]
Sutter et al., “Structural basis of enzyme encapsulation into a bacterial nanocompartment,”
[cited by applicant]
Urich et al., “X-ray Structure of a Self-Compartmentalizing Sulfur Cycle Metalloenyzme,”
[cited by applicant]
Van de Winkel et al., “Biology of Human Immunoglobulin G Fc Receptors,”
[cited by applicant]
Vicente et al., “Large-scale production and purification of VLP-based vaccines,”
[cited by applicant]
Ward et al., “The effector functions of immunoglobulins: implications for therapy,”
[cited by applicant]
Wines et al., “The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors FcγRI and FcγRIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A,”
[cited by applicant]
Wu, Jingjing, “Blinatumomab: a bispecific T cell engage (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia,”
[cited by applicant]
Zhang et al., “Self-Assembly in the Ferritin Nano-Cage Protein Superfamily,”
[cited by applicant]
Zhang et al., “X-ray structure analysis and crystallographic refinement of lumazine synthase from the hyperthermophile
[cited by applicant]
Zhu et al., “QS-21: A Potent Vaccine Adjuvant,”
[cited by applicant]
Espinosa et al., “Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein is a Target of Protective Antibodies,” Journal of Infectious Diseases, Oct. 1, 2015, 212(7):1111-1119, e-published Mar. 11, 20…
[cited by applicant]
Altshuler et al. “Production of recombinant antibodies and methods for increasing their affinity” [in Russian], Advances in Biological Chemistry, 2010, vol. 50, p. 203 (title page), 215, 216 and 219-228 and the English …
[cited by applicant]